A new study by scientists at ARIAD provides an overview of the design of small molecule drugs to treat drug-resistant leukemia
options for CML patients who do not respond to first-and second-generation targeted therapies, or are intolerant to these treatments. This detailed structural analysis of mutation T315I was a key step in our effort to design a new targeted therapy for leukemia, said Tim horn, Ph.D., Chief Scientific Officer of ARIAD. These data confirm the plans underway to develop AP24534 in various forms of leukemia and to submit an investigational new drug application for AP24534 by the end of the year.Preclinical studies presented in the last years of the American Society of Hematology demonstrated that AP24534 may block the growth of tumors expressing this genetic variant and increased survival in difficult conditions to treat animal models. AP24534 is a potent inhibitor of VEGF and
FGF receptor families, which are fundamental to the process of tumor angiogenesis - the growth of new blood vessels in tumors, providing support for the use of AP24534 beyond CML in the treatment of solid tumors.Reference: T. Zhou, Parillon L., Li F., et al: (2007) The crystal structure of Abl T315I mutant kinase. Chemical Biology and Drug Design 70:171-181. About ARIAD ARIAD involved in discovering and developing drugs to treat cancer by regulating cell signaling with the development of small molecules. ARIAD is developing a comprehensive approach to cancer patients referred to a medical need - aggressive disease and advanced cancer for which current treatments are inadequate.ARIAD has a global partnership with Merck Co., Inc. to develop and commercialize deforolimus,
ARIAD Lead Cancer Product Candidate. Medinol Ltd. is also developing deforolimus-eluting stents to prevent restenosis of injured vessels following interventions in which stents are used in conjunction with balloon angioplasty. ARIAD has an exclusive license for the innovative technology and patents related to certain methods of treatment of NF-kB, and the discovery and development of drugs to regulate NF-kB cell-signaling Pages: 1 [2] 3 4